Results 61 to 70 of about 56,513 (348)

The pathogenesis of mucositis : updated perspectives and emerging targets [PDF]

, 2019
Mucositis research and treatment are a rapidly evolving field providing constant new avenues of research and potential therapies. The MASCC/ISOO Mucositis Study Group regularly assesses available literature relating to pathogenesis, mechanisms, and novel
Correa, ME, Correa, M. E., Correa, M.E., Bossi, P., Bossi, P, Bateman, E, Lalla, R.V., Sonis, S, Thorpe, D, Al-Dasooqi, N., Mayo, B., Stringer, A., Al-Dasooqi, N, Sebille, Y. Van, Al-Azri, A., Wardill, H, Al-Azri, A, Bowen, J, Raber-Durlacher, J, ten Bohmer, K., Bateman, E., Bohmer, K. ten, Stringer, A, Thorpe, D., Wardill, H., Cheng, K., Sonis, S., van Sebille, Y, Lalla, RV, Bowen, J., Van Sebille, Y., Mayo, B, Lalla, R. V., Elad, S, Kandwal, A, ten Bohmer, K, Cheng, K, Kandwal, A., Elad, S., Nair, RG, Nair, R. G., Raber-Durlacher, J., Nair, R.G.   +42 more
core   +1 more source

Treatment‐Related Adverse Events and Health‐Related Quality of Life Associated With Immune Checkpoint Inhibitor Treatment for Mucosal Head and Neck Squamous Cell Carcinoma: A Scoping Review

Head &Neck, EarlyView.
ABSTRACT Background Supportive care needs of patients receiving immune checkpoint inhibitors (ICIs) for head and neck squamous cell carcinoma (HNSCC) are ill‐defined. Hence, known treatment‐related adverse events (TRAEs) and health‐related quality of life (HRQoL) associated with ICI treatment for HNSCC were examined to inform future supportive care ...
N. D. O'Donnell, E. C. Ward, L. R. Wishart, R. Perera, C. Barrett, K. A. Edmiston, E. Mitchell, A. Pigott, R. Pitt, K. Russell, B. A. Chan, R. Ladwa   +11 more
wiley   +1 more source

New pathways for alimentary mucositis [PDF]

, 2008
Alimentary mucositis is a major dose-limiting toxicity associated with anticancer treatment. It is responsible for reducing patient quality of life and represents a significant economic burden in oncology.
Keefe, D., Bowen, J., Joanne M. Bowen, Dorothy M. K. Keefe   +3 more
core   +1 more source

The science of mucositis [PDF]

Supportive Care in Cancer, 2022
Joanne Bowen, Hannah Wardill
openaire   +2 more sources

Longitudinal Swallowing and Salivary Changes With CLR 131 and Re‐Irradiation in Recurrent Head and Neck Cancer

Head &Neck, EarlyView.
ABSTRACT Background Patients with recurrent head and neck cancer (HNC) often present with severe, persistent dysphagia and xerostomia following prior chemoradiation. Although swallowing impairments and salivary dysfunction have been reported in this population, prior longitudinal studies have not examined changes in salivary composition or how these ...
Jenni Wu, Sara Gustafson, Meredith Hyun, Roxana Alexandridis, Mark Nicosia, Timothy McCulloch, Justine Bruce, Randall Kimple, Nicole Rogus‐Pulia   +8 more
wiley   +1 more source

“It's the Exact Same Treatment … Except Only 5 Min Away”: A RE‐AIM Evaluation of a Speech‐Language Pathology Shared‐Care Model for Rural Patients With Head and Neck Cancer

Head &Neck, EarlyView.
ABSTRACT Background Challenges accessing post‐treatment speech‐language pathology (SLP) services can add to treatment burden for rural patients with head and neck cancer (HNC). Hence, the aim of this study was to evaluate a shared‐care SLP service designed to support local SLP access for patients with HNC, using the RE‐AIM framework.
Corey Patterson, Elizabeth C. Ward, Rebecca L. Packer, Jasmine Foley, Laurelie R. Wishart, Clare L. Burns, Sally Pether, Wendy Comben   +7 more
wiley   +1 more source

Methotrexate and mucositis: A merry-go-round for oncologists

Indian Journal of Medical and Paediatric Oncology, 2019
High-dose methotrexate is the backbone of various regimens for treating lymphoid malignancies. Mucositis is a well-known, dose-related side effect of methotrexate.
Kundan Mishra, Aditya Jandial, Anil Kumar, Deepesh Lad, Gaurav Prakash, Alka Khadwal, Pankaj Malhotra   +6 more
doaj   +1 more source

Oral mucositis

National Journal of Maxillofacial Surgery, 2020
Oral mucositis is one of the most common complications of cancer therapy. It is a nonhematologic complication of cytotoxic chemotherapy and radiotherapy and reduces the quality of life. It is estimated that 40% the cases on standard chemotherapy may develop oral mucositis.
Singh, Vibha, Singh, Akhilesh Kumar
openaire   +3 more sources

Randomized Phase II Trial of Consolidation Pembrolizumab After Definitive Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma: KCSG HN19‐09, CONPELAN Study

Head &Neck, EarlyView.
ABSTRACT Background The benefit of consolidation programmed cell death protein 1 (PD‐1) blockade after chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma (NPC) remains unclear. Methods Patients with stages II–IVB NPC were randomized (2:1) to pembrolizumab 200 mg or placebo every 3 weeks for up to 17 cycles after chemoradiotherapy ...
Sang Hoon Chun, Seyoung Seo, Jang Ho Cho, Keon‐Uk Park, Sang‐Cheol Lee, Yong Won Choi, Tak Yun, Seong Hoon Shin, Sung‐Bae Kim, Seungeun Lee, Chang Ho Ahn, Bhumsuk Keam   +11 more
wiley   +1 more source

Oral Administration of Surface-Deacetylated Chitin Nanofibers and Chitosan Inhibit 5-Fluorouracil-Induced Intestinal Mucositis in Mice [PDF]

This study investigated the prophylactic effects of orally administered surface-deacetylated chitin nanofibers (SDACNFs) and chitosan against 5-fluorouracil (5-FU)-induced intestinal mucositis, which is a common side effect of 5-FU chemotherapy.
Azuma, Kazuo, 50194410, Okamoto, Yoshiharu, 2273, Imagawa, Tomohiro, 80264654, Osaki, Tomohiro, 100001158, 2885, 100000741, 30432610, 20232605, Ito, Norihiko, 70402980, 100000469, 100000602, Ochi, Kosuke, 4721, 100000923, 4868, 100000607, 50721841, 4641, Tsuka, Takeshi, Izawa, Hironori, Morimoto, Minoru, 26766, 26765, Saimoto, Hiroyuki, 4816, Koizumi, Ryo, 100001168, Ifuku, Shinsuke, 100000597, 40431332, 10273880, 50643235, 20186977, 4897, 100000515, 100000637, 4711, 4634, 4637   +43 more
core   +1 more source